ITN News

Celebrate Ten Years of Tolerance!

ndarbous — Mon, 19 Jul 2010 12:54:59 -0700

This year marks the Immune Tolerance Network's 10th anniversary! To celebrate, the ITN invites you to attend a one day symposium - "Ten Years of Tolerance" on November 1, 2010 at the National Institutes of Health in Bethesda, MD.

Possible first new treatment for ANCA-associated vasculitis in 40 years

itn_admin — Thu, 15 Jul 2010 14:09:09 -0700

Results of an Immune Tolerance Network clinical trial may provide doctors with another weapon in the treatment of ANCA-associated vasculitis, which has seen no new approved treatments in 40 years. The study, published in the New England Journal of Medicine, showed that the drug rituximab provides the same treatment benefits as the existing standard of care, and appears to offer additional benefits to those suffering relapses.

Kidney transplant tolerance “signatures” published in two separate JCI reports

itn_admin — Wed, 26 May 2010 14:15:19 -0700

The results of two Immune Tolerance Network (ITN)-sponsored efforts in identifying genetic and cellular signatures of transplant tolerance were published this week in the Journal of Clinical Investigation. The signatures are patterns of gene expression and cell types that were found to be characteristic of a set of rare patients who developed a natural tolerance for their kidney transplant – meaning they do not require anti-rejection medications.

Request for Proposals - Clinical Trials in Immune Tolerance

lstraub — Mon, 26 Apr 2010 10:57:49 -0700

The ITN is currently seeking Concept Proposals for novel clinical trials designed to induce immune tolerance in Type 1 Diabetes, transplantation, autoimmune diseases, and allergy and asthma. In addition the ITN accepts applications for the development of novel tolerance assays or mechanistic studies for the purposes of establishing new surrogate biomarkers of immune tolerance and investigating the mechanisms of clinical tolerance. Proposals should be submitted via our site: http://www.immunetolerance.org/professionals/proposals/guidelines

Recommendations of ITN/JDRF Combination Therapy Assessment Group published

itn_admin — Mon, 12 Apr 2010 14:41:29 -0700

The recommendations of the ITN//JDRF Type 1 Diabetes Combination Therapy Assessment Group have been published in the May 2010 issue of Clinical & Experimental Immunology.

Benaroya Research Institute's Jerry Nepom named Immune Tolerance Network director

itn_admin — Tue, 06 Apr 2010 10:33:39 -0700

SEATTLE – The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has named Gerald T. Nepom, MD, PhD, as the director of the Immune Tolerance Network, one of the largest government-funded clinical research networks in the country working to establish new treatments for diseases of the immune system. Dr. Nepom is presently the director of Benaroya Research Institute at Virginia Mason (BRI) and will maintain both positions providing scientific oversight and management.

ITN Director Bluestone appointed Executive Vice Chancellor and Provost at UCSF

itn_admin — Fri, 26 Feb 2010 07:40:32 -0800

ITN Director and founder, Jeffrey A. Bluestone has accepted the position of Executive Vice Chancellor and Provost at the University of California, San Francisco, pending approval by the UC Regents.

Details of his new appointment may be found on the UCSF website .

As he embarks upon his latest challenge at UCSF, Bluestone will step down as Director of the Immune Tolerance Network.

ITN’s START study of Newly Diagnosed Type 1 Diabetes begins Pediatric Enrollment

itn_admin — Wed, 20 Jan 2010 17:17:11 -0800

The ITN's START research trial for new-onset type 1 diabetes has received the approval of its Data Safety and Monitoring Board to accept patients aged 12-18 years into the study. The decision was made after a review of safety data from the initial group of 10 adult subjects enrolled into the study. The trial is now open to individuals between the ages of 12-35 who have been diagnosed with new-onset type 1 diabetes within the past 3 months. The START trial is being conducted under the direction of principal investigator Dr.

Results of ITN insulin B-chain study for type 1 diabetes published

itn_admin — Wed, 09 Dec 2009 12:32:19 -0800